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Abstract The use of multiple medicines (polypharmacy)
is increasingly common in middle-aged and older popula-
tions. Ensuring the correct balance between the prescribing
of ‘many’ drugs and ‘too many’ drugs is a significant
challenge. Clinicians are tasked with ensuring that patients
receive the most appropriate combinations of medications
based on the best available evidence, and that medication
use is optimised according to patients’ clinical needs (ap-
propriate polypharmacy). Historically, polypharmacy has
been viewed negatively because of the associated medi-
cation safety risks, such as drug interactions and adverse
drug events. More recently, polypharmacy has been iden-
tified as a risk factor for under-prescribing, such that
patients do not receive necessary medications and this can
also pose risks to patients’ safety and well-being. The
negative connotations that have long been associated with
the term polypharmacy could potentially be acting as a
driving factor for under-prescribing, whereby clinicians are
reluctant to prescribe necessary medicines for patients who
are already receiving ‘many’ medicines. It is now recog-
nised that the prescribing of ‘many’ medicines can be
entirely appropriate in patients with several chronic con-
ditions and that the risks of adverse drug events that have
been associated with polypharmacy may be greatly reduced
when patients’ clinical context is taken into consideration.
In this article, we outline the current perspectives on
polypharmacy and make the case for adopting the term
‘appropriate polypharmacy’ in differentiating between the
prescribing of ‘many’ drugs and ‘too many’ drugs. We also
outline the inherent challenges in doing so and provide
recommendations for future clinical practice and research.
Key points
Despite the fact that the prescribing of multiple
medicines (polypharmacy) is increasingly common
in middle-aged (age 45–64 years) and older
populations (age C65 years), the term
‘polypharmacy’ continues to lack a universally
accepted definition.
Recent cohort studies using population datasets have
challenged long-standing assumptions that
polypharmacy is always hazardous, or indicative of
poor care, and have highlighted the importance of
considering the clinical context underlying
prescribing.
The concept of ‘appropriate polypharmacy’
recognises that patients can benefit from multiple
medications provided that prescribing is evidence
based, reflects patients’ clinical conditions and
considers potential drug interactions. This concept
should be promoted in place of existing thresholds
that define the term ‘polypharmacy’ using an
arbitrary number of medicines.
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1 Introduction
The prescribing of multiple medicines, or polypharmacy, is
increasingly common in clinical practice, particularly in
older people (age C65 years) [1–3]. This is likely owing to
multiple factors including increasing life expectancy and
the consequent growth in the prevalence of multimorbidity
(i.e. the presence of two or more long-term conditions), as
well as the enhanced availability of effective drug treat-
ments and prescribing guidelines that advocate the use of
more than one drug in the prevention and management of
various health conditions [4, 5].
Polypharmacy is often clinically indicated and beneficial
in specific conditions (e.g. diabetes mellitus, hypertension)
and patient populations (e.g. patients with multimorbidity).
However, the use of multiple medicines poses medication
safety risks to patients [5, 6]. For example, a repeated
cross-sectional analysis of community-dispensed prescrib-
ing data for 310,000 adults in Scotland found that the
number of dispensed medications was the characteristic
most strongly associated with potentially serious drug–drug
interactions; 81 % of patients receiving C15 drugs were
exposed to potentially serious interactions compared with
11 % of those dispensed two to four drugs [5]. Drug
interactions are a form of adverse drug event (ADE) that
have been identified as a preventable cause of medication-
related hospitalisations [7, 8]. Balancing the clinical ben-
efits and safety risks associated with the use of multiple
medications is a difficult task; hence, polypharmacy has
been described as one of the greatest prescribing challenges
[9].
This article outlines current perspectives on polyphar-
macy, makes the case for adopting the term ‘appropriate
polypharmacy’ in ensuring patient safety, and outlines the
inherent challenges for practice and research in doing so.
2 Polypharmacy: ‘Many’ Medicines or ‘Too
Many’ Medicines?
One of the challenges in discussing polypharmacy and the
associated medication safety implications is that the term
itself currently lacks a universally accepted definition.
Although we have referred to polypharmacy as the pre-
scribing of multiple medicines, it is also commonly defined
using a numerical threshold (e.g. co-prescribing of four or
five medications) [10, 11]. The term can also have a dual
meaning [12, 13]. For example, polypharmacy can refer to
the prescribing of ‘many drugs’ or ‘too many’ drugs, the
former being entirely appropriate [12]. Polypharmacy has
often been viewed negatively and seen to signify inap-
propriate drug therapy or ‘too many’ drugs [12, 13].
Observational studies have highlighted the association
between polypharmacy in older people and potentially
inappropriate prescribing (PIP) [14, 15], as well as negative
clinical outcomes that pose risks to patients’ safety and
well-being (e.g. ADEs, medication non-adherence) [11].
Hence, interventions aimed at improving the appropriate-
ness of prescribing for patients receiving polypharmacy
have often focussed on reducing the number of prescribed
medications [16].
However, interventions that seek to solely reduce the
number of prescribed medicines fail to consider inappro-
priate prescribing in its entirety. Inappropriate prescribing
does not only encompass over-prescribing (prescribing of
more drugs than clinically necessary) and mis-prescribing
(incorrect prescribing of a necessary drug), it also includes
under-prescribing (failure to prescribe a clinically indicated
drug) [17, 18]. Under-prescribing is common in older
patients and the associated clinical consequences pose
safety risks to patients (e.g. ischaemic stroke in patients
undertreated for atrial fibrillation) [19]. Polypharmacy has
been associated with under-prescribing in older people [20,
21]. For example, Kuijpers et al. [20] showed that a sig-
nificantly higher proportion of patients receiving
polypharmacy (defined as four or more medicines) were
under-treated (42.9 %) compared with those receiving
fewer medicines (13.5 %). It has been speculated that fear
of causing ADEs is contributing to under-prescribing by
clinicians [19] and this could partly account for the
reported reluctance among clinicians to initiate new med-
ications in patients receiving polypharmacy [22].
Recent cohort studies using population datasets have
challenged existing assumptions that polypharmacy is
always hazardous, or indicative of poor care, and have
highlighted the importance of considering the clinical
context underlying prescribing [23, 24]. For example, an
analysis of Scottish primary care data linked to hospitali-
sations for a sample of approximately 180,000 adults
showed that the strength of the association between the
number of regular medicines and unplanned hospitalisa-
tions was greatly reduced when the number of clinical
conditions was accounted for [23]. As noted by Guthrie
et al. [5] polypharmacy is ‘‘potentially problematic rather
than always inappropriate’’ and, as such, assessments of
prescribing appropriateness need to extend beyond the
number of drugs prescribed and consider co-existing
medical conditions in differentiating between ‘many’ and
‘too many’ medicines.
Owing to the lack of a universally accepted definition,
there have been calls to abandon the term polypharmacy in
favour of terms such as ‘hyperpharmacotherapy’ or
‘polytherapy’ [13, 25]. However, it is difficult to see this
happening because of the term’s widespread use in the
literature. Instead, an arguably better solution to this long-
standing issue would be to follow Aronson’s
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recommendation and qualify the term as either appropriate
or inappropriate [12]. A recent report published by the
King’s Fund in the UK has promoted the term ‘appropriate
polypharmacy’, described as ‘prescribing for an individual
with complex or multiple conditions where medicine use
has been optimised and prescribing is in accordance with
best evidence’, rather than existing thresholds that define
polypharmacy based on the number of prescribed medi-
cations [26]. The concept of ‘appropriate polypharmacy’
recognises that patients can benefit from multiple medi-
cations provided that prescribing is evidence based and
reflects patients’ clinical needs. Greater use of this term
may help to dispel existing misconceptions that polyphar-
macy signifies ‘too many’ medicines and reduce reluctance
among clinicians to initiate necessary medicines in patients
already receiving polypharmacy.
3 Challenges of Ensuring Appropriate
Polypharmacy
Widespread adoption of the term ‘appropriate polyphar-
macy’ is by no means straightforward. Considerable chal-
lenges need to be overcome to enable its use by both
researchers and clinicians in terms of establishing methods
for identifying patients at risk of PIP and operationalising
the core concepts of appropriate polypharmacy in clinical
practice, i.e. evidence-based prescribing and medicines
optimisation.
3.1 Identifying Patients with Medication Safety
Risks
The use of numerical thresholds as a screening tool for
polypharmacy has long provided a relatively straightfor-
ward method for identifying patients deemed at risk of PIP
or ADEs. However, the validity of this approach appears to
be questionable [27–29]. For example, using a cohort of
older trial participants, Belfrage et al. [27] examined the
concurrent validity of the number of prescribed drugs as an
indicator of prescribing quality (i.e. ability to differentiate
between appropriate and suboptimal treatment). The
authors showed that a cut-off indicator of five or more
medicines had acceptable sensitivity (14 % of patients
receiving suboptimal treatment were not identified) but
poor specificity (47 % of identified patients were not
receiving suboptimal treatment) in detecting PIP using a
validated assessment tool as the gold standard (i.e. STOPP/
START [30]). They also identified an inverse relationship
between the parameters of sensitivity and specificity.
Sensitivity was found to decline rapidly when a larger
number of medications were used as a cut-off indicator
whereby higher proportions of patients requiring treatment
optimisation would not be identified (Fig. 1).
The King’s Fund report proposed a pragmatic approach
for identifying patients with ‘higher-risk polypharmacy’
(e.g. C10 medications), noting, as already stated, that there
is no ideal and universally applicable definition for iden-
tifying polypharmacy [26]. In cases where numerical
thresholds are used, it must be recognised that a proportion
of patients receiving inappropriate medications will be
overlooked (Fig. 1). A targeted approach, focussing on
specific drug classes that contribute to PIP, has been pro-
posed as a more suitable method that may provide greater
sensitivity in identifying patients with medication safety
risks [13, 29].
3.2 Polypharmacy and Appropriate Prescribing
Ensuring that prescribing is evidence based is one of the
key challenges to achieving appropriate polypharmacy,
particularly in older people and patients with multimor-
bidity. It is well recognised that evidence to support pre-
scribing decisions in older people is lacking because of
their under-representation in clinical trials [31]. Further-
more, prescribing guidelines typically focus on single
diseases and when applied to complex multimorbid
patients, they often fail to provide guidance on how to
prioritise treatment recommendations and can act as a
driving force for polypharmacy [32].
A number of recent developments have sought to
address some of these issues. For example, a working
group in Scotland has published guidance that outlines a
seven-step structured process for conducting medication
reviews with patients receiving polypharmacy [33]. An
expert panel from the American Geriatrics Society has
developed a set of guiding principles on the management of
older patients with multimorbidity [34] (Fig. 2). These
guidance sources outline a patient-centred approach to
ensuring safe and appropriate medicine use. In addition to
these resources, the National Institute for Health and Care
Excellence in the UK is currently developing guidelines for
the clinical assessment and management of patients with
multimorbidity [35]. However, it will be some time before
the clinical impact of these resources is known.
Various tools have been developed to assess prescribing
appropriateness, primarily in older populations [18]. These
assessment tools have typically been developed using
consensus-based exercises (e.g. Delphi panels), to formu-
late an evidence base where higher levels of evidence (e.g.
controlled trials) are lacking [18]. Although the current
literature on polypharmacy primarily focuses on the older
population, the use of multiple medicines is by no means
limited to older people. Multimorbidity is also highly
prevalent in middle-aged people (age 45–64 years) [36].
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Despite a dearth of prescribing evaluations among this
population cohort [37], emerging evidence shows that
polypharmacy is increasingly common in middle-aged
people [5, 38], thus, exposing them to medication safety
risks. A set of prescribing criteria known as PROMPT
(PRescribing Optimally in Middle-aged People’s Treat-
ments) has been developed specifically for use in middle-
aged adults [37].
Prescribing assessment tools can play an important role
in identifying and addressing PIP. However, there are
limitations associated with their clinical application in
ensuring appropriate polypharmacy. For example, they do
not provide guidance as to how treatment decisions should
be prioritised and in many cases, predictive validity has not
been established [39]. Therefore, the clinical impact of
improvements in prescribing appropriateness on patient
safety is unclear. Furthermore, as there is no universal
indicator of appropriate polypharmacy, these tools act as
surrogate markers and additional amendments may be
required to ensure that prescribing is appropriate for indi-
vidual patients.
3.3 Polypharmacy and Medicines Optimisation
Another key challenge to achieving appropriate polyphar-
macy relates to optimising patients’ medicine use.
Medicines optimisation is a person-centred approach aimed
at ensuring the best clinical outcomes for patients through
safe and effective use of medicines [40]. Medicines opti-
misation centres on shared decision making that considers
an individual patient’s needs, preferences, and values.
Optimising polypharmacy involves ‘‘encouraging the use
of appropriate drugs, in a way that the patient is willing and
able to comply with, to treat the right diseases’’, as well as
targeting both over-prescribing and under-prescribing [26].
Efforts to optimise polypharmacy often focus on tar-
geting over-prescribing, thereby reducing treatment bur-
den. This is exemplified by the emergence of the term
‘deprescribing’ that is featuring increasingly in the litera-
ture. Deprescribing has been defined as ‘‘the systematic
process of identifying and discontinuing drugs in instances
in which existing or potential harms outweigh existing or
potential benefits within the context of an individual
patient’s care goals, current level of functioning, life
expectancy, values, and preferences’’ [41]. Deprescribing
has been described as a patient-centred process that forms
part of the good prescribing continuum and has been pro-
moted as a strategy for reducing polypharmacy and
improving patients outcomes [41–43]. However, it is
important to note that deprescribing deals with only one
aspect of inappropriate prescribing (i.e. over-prescribing).
Although it has been postulated that deprescribing may
indirectly serve to reduce under-prescribing [42], this has
not been established. More importantly, evidence to sup-
port the entire process is lacking and claims of benefits are
often based on indirect evidence and inferences from pre-
vious research involving older people [44, 45]. Further-
more, a recent systematic review of observational studies
that examined clinical outcomes in community-dwelling
older patients receiving multiple medicines, found that
evidence was mixed regarding the relationship between
polypharmacy and adverse outcomes such as falls, hospi-
talisations and mortality [46]. Thus, the associations
between polypharmacy and negative clinical outcomes
might not be as well established as previously believed,
particularly because many studies did not adequately
account for comorbidity as a confounding factor. It is clear
that if appropriate polypharmacy is to be achieved,
deprescribing cannot be considered in isolation when
optimising patients’ medications, particularly as potentially
Fig. 1 Plot of cut-off indicator
vs sensitivity and specificity
(adapted from Belfrage et al.
[27])
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inappropriate omissions have been found to be more
prevalent than potentially inappropriate prescriptions in
older patients [21]. Notwithstanding the above limitations,
the process of optimising polypharmacy could benefit from
elements of the deprescribing process (e.g. systematic
approach to medication review, addition of expiration dates
to medication regimens to prompt reviews) [41].
In optimising polypharmacy, it is also important to note
that efforts to ensure safe and effective medicine use are
not determined solely by the number of medications pre-
scribed. Additional factors contribute to the overall com-
plexity of drugs regimens (i.e. formulation types, dosing
frequency, further directions). These factors have been
incorporated into the Medication Regimen Complexity
Fig. 2 Structured approach for
evaluating and managing older
adults with multimorbidity
(adapted from the American
Geriatrics Society [34])
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Index, a validated tool that can be used to quantify drug
regimen complexity [47]. Despite being more time con-
suming to apply than simple medication counts, this index
could encourage greater consideration of important and
modifiable factors (e.g. dosing frequency, additional
directions) other than the number of medications in opti-
mising polypharmacy. This may also help to ensure that
patients are willing and able to adhere to the prescribed
medication regimen. Medication adherence is an important
clinical issue in ensuring safe and effective medicine use as
it has been estimated that 50 % of patients do not take their
medications correctly [48]. Polypharmacy is associated
with medication non-adherence in older people [11] and
although few studies have assessed the full range of factors
that contribute to medication regimen complexity, higher
Medication Regimen Complexity Index scores have been
associated with lower adherence in older patients [49]. Few
trials of interventions seeking to improve appropriate
polypharmacy in older people have examined patient
adherence as an outcome measure [10]. However, there is
some evidence to suggest that regimen simplification (e.g.
reduction in dosing frequency) may be an important effect
moderator for interventions aimed at improving adherence
in this patient cohort [50].
4 Recommendations for Future Clinical Practice
and Research
In ensuring the prescribing of appropriate polypharmacy,
researchers and clinicians need to maintain a broad focus.
The challenges posed by the prescribing of polypharmacy
are neither limited to the older population nor the pre-
scribing of ‘too many’ drugs. In the absence of a univer-
sally applicable, valid and reliable measure of appropriate
polypharmacy, future assessments of prescribing appro-
priateness should assess both under-prescribing and over-
prescribing across all adult populations using validated
tools as surrogate markers (e.g. STOPP/START [51],
PROMPT [37]). Medication regimen complexity should
also be considered to reduce factors other than the absolute
number of medications that contribute to the overall
treatment burden (e.g. dosing frequency). This could ulti-
mately enhance medication adherence.
Efforts to optimise polypharmacy should adopt a
patient-centred approach as advocated by recent guidance
[33, 34]. It is important to recognise that appropriate
polypharmacy is not a fixed end-point but rather an ideal
concept. The threshold that differentiates between the
prescribing of ‘many’ drugs and ‘too many’ drugs will not
only vary according to individual patient’s clinical condi-
tions, but also over time. For example, as multimorbid
patients age and become frail, preventive medications
become less meaningful, and clinicians must establish
when it is appropriate to transition from disease-modifying
treatment to a palliative approach, whereby medications
are reduced or discontinued [26]. Accordingly, regular
medication reviews will serve an increasingly important
function in ensuring appropriate prescribing according to
patients’ existing clinical conditions and life expectancy.
In the absence of a universal indicator with suit-
able sensitivity and specificity for identifying patients
receiving inappropriate polypharmacy, it may be better to
focus on specific drug classes that pose safety risks.
Researchers and clinicians can draw from the existing body
of observational research on PIP to identify suitable target
drug classes.
Finally, more attention needs to be paid to the clinical
outcomes associated with appropriate polypharmacy.
A Cochrane review of interventions to improve appropriate
polypharmacy in older people highlighted that assessments
of clinically relevant outcomes (e.g. quality of life) have
been lacking in trials to date and, where assessed, findings
have often been inconsistent or difficult to compare
because of heterogeneity in measurement scales [10].
Increasing emphasis is being placed on the importance of
‘core outcome sets’ (COS) as an agreed and standardised
set of outcomes that should be measured and reported, as a
minimum, in all trials in a specific clinical area [52]. COS
are intended to ensure that selected outcomes are relevant
to key stakeholders and to overcome problems with
heterogeneity in outcome measurements that have hindered
the pooling of data in systematic reviews. Ongoing work as
part of the COMET (Core Outcome Measures in Effec-
tiveness Trials) initiative is seeking to establish rigorous
methods for developing COS [52, 53] and future research
should focus on developing a COS for trials of interven-
tions aimed at improving appropriate polypharmacy.
5 Conclusion
In current clinical practice where the prescribing of mul-
tiple medicines is increasingly common in adults with
multimorbidity and advanced age, differentiating between
‘many’ drugs and ‘too many’ drugs is proving ever more
complex. Previous assumptions that polypharmacy is syn-
onymous with ‘too many’ medicines or inappropriate pre-
scribing have been undermined because when patients’
clinical context is taken into consideration, the prescribing
of ‘many’ medicines can, in fact, be entirely appropriate.
Conceptualising polypharmacy as a numerical threshold is
unhelpful because it fails to consider that the appropriate
number of medicines varies according to individual
patients’ clinical needs and may overlook the omission of
potentially beneficial medications, which can equally pose
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risks to patients’ safety and well-being. We contend that, as
a stand-alone term, polypharmacy should be interpreted as
the prescribing of multiple medicines and, rather than
quantifying the term according to the number of prescribed
medicines, greater emphasis should be placed on qualifying
the term based on the clinical appropriateness of the
combination of medicines for the individual patient.
Increased use of the term ‘appropriate polypharmacy’
could encourage greater consideration of the clinical con-
text underlying prescribing, as well as increased acceptance
that the prescribing of multiple medicines is ‘potentially
problematic rather than always inappropriate’.
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